| 10.1597 0.005 (0.05%) | 09-23 10:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.97 | 1-year : | 12.06 |
| Resists | First : | 10.24 | Second : | 10.32 |
| Pivot price | 10.16 | |||
| Supports | First : | 10.11 | Second : | 8.41 |
| MAs | MA(5) : | 10.16 |
MA(20) : | 10.15  |
| MA(100) : | 10.09 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 23.4 |
| RSI | RSI(14): 51.5 | |||
| 52-week | High : | 10.32 | Low : | 9.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DMII ] has closed above bottom band by 13.3%. Bollinger Bands are 36.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.17 - 10.23 | 10.23 - 10.28 |
| Low: | 10 - 10.07 | 10.07 - 10.14 |
| Close: | 10.05 - 10.16 | 10.16 - 10.26 |
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
Thu, 17 Sep 2026
Drugs (DMII) Stock Alert: Dead Money at $10.16 — Or Is It? 2026-09-17 - Donchian Channel - siam.in
Wed, 02 Sep 2026
Drugs Made In America Acquisition II (DMII) Holds at $10.15 as SPAC Shares Trade Flat Within Range - Quality ETF - careplusvn.com
Sun, 16 Aug 2026
DMII Holds at $10.13: Drugs Made In America Acquisition II Corp. Trades Flat Amid SPAC Market Consolidation - Dark Pool Sentiment - dars.gov.et
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Financial - Conglomerates
|
|
| Shares Out | 64 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 15.2 (%) |
| Held by Institutions | 72.4 (%) |
| Shares Short | 122 (K) |
| Shares Short P.Month | 47 (K) |
| EPS | 0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.29 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 35.01 |
| PEG Ratio | 0 |
| Price to Book value | -36.27 |
| Price to Sales | 0 |
| Price to Cash Flow | -505.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|